

## Nepal

### Support for Vaccine: Rotavirus

This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** Nepal

2. **Vaccine grant number:** NPL-RV-R

3. **Date of Decision Letter:** 22 September 2020

4. **Date of the Partnership Framework Agreement:** 22 August 2014

5. **Programme title:** New Vaccine Support (NVS), Rotavirus, Routine

6. **Vaccine type:** Rotavirus

7. **Requested product presentation and formulation of vaccine:**

*Rrix, 1 dose/plastic tube, liquid*

8. **Programme duration:<sup>1</sup>** 2020-2021

9. **Programme Budget (indicative):<sup>2</sup>** (subject to the terms of the Partnership Framework Agreement, if applicable)

|                        | 2020      | 2021      | 2022 | 2023 | 2024 | 2025 | Total <sup>3</sup> |
|------------------------|-----------|-----------|------|------|------|------|--------------------|
| Programme Budget(US\$) | 2,129,863 | 2,643,110 | -    | -    | -    | -    | 4,772,973          |

10. **Vaccine introduction grant:**

| Approval |              |               |
|----------|--------------|---------------|
| Year     | Grant number | Amount (US\$) |
| 2020     | NPL-RV-R-VIG | 514,078       |

11. **Product switch grant:**

Not applicable

<sup>1</sup>This is the entire duration of the programme.

<sup>2</sup>This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

<sup>3</sup>This is the amount that Gavi has approved.

**12. Indicative annual amounts:**<sup>3</sup> (subject to the terms of the Partnership Framework Agreement, if applicable)

| Type of supplies to be purchased with Gavi funds | 2020      | 2021      | 2022 |
|--|-----------|-----------|------|
| Number of vaccine doses                          | -         | 1,213,500 | -    |
| Number of AD syringes                            | -         | -         | -    |
| Number of re-constitution syringes               | -         | -         | -    |
| Number of safety boxes                           | -         | -         | -    |
| Annual Amounts (US\$)                            | 2,129,863 | 2,643,110 | -    |

**13. Procurement agency:** UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

**14. Self-procurement:**  
Not applicable

**15. Co-financing obligations:**

| According to the co-financing policy, the Country falls within the group:   | Initial self-financing |      |      |      |      |
|---|------------------------|------|------|------|------|
| The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year. |                        |      |      |      |      |
| Type of supplies to be purchased with Country funds in each year  | 2021                   | 2022 | 2023 | 2024 | 2025 |
| Number of vaccine doses   | 123,000                | -    | -    | -    | -    |
| Number of AD syringes   | -                      | -    | -    | -    | -    |
| Number of re-constitution syringes  | -                      | -    | -    | -    | -    |
| Number of safety boxes  | -                      | -    | -    | -    | -    |
| Value of vaccine doses (US\$)   | 262,458                | -    | -    | -    | -    |
| Total co-financing payments (US\$) (including freight)  | 267,891                | -    | -    | -    | -    |

**16. Operational support for campaigns:**  
Not applicable

**17. Additional Reporting Requirements:**

| Reports and other information :   | Due dates                                 |
|---|---|
| <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>● vaccine stock levels including buffer stock, by end of March;</li> <li>● number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>● Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> | <p>31 March<br/>15 May</p>                |
| <p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>  | <p>To be agreed with Gavi Secretariat</p> |


**18. Financial clarifications:**

Not applicable

**19. Other conditions:**

Not applicable

Signed by,  
On behalf of Gavi,



Pascal Bijleveld,  
Director Country Support  
28 September 2020